M.‐T. Leccia

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay, J. Cadranel, Amélie Lusque et al. · European Respiratory Journal · 2017 · 421 citations · Full text

Medicine, Immunology, Oncology +15

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL

Caroline Aspord, M.‐T. Leccia, J. Charles et al. · Cancer Immunology Research · 2013 · 188 citations · Full text

Medicine, Immunology, Oncology +13

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

E. Maubec, Marouane Boubaya, Peter Petrow et al. · Journal of Clinical Oncology · 2020 · 174 citations

Medicine, Oncology, Pharmacology +16

A Multistep Voriconazole-Related Phototoxic Pathway May Lead to Skin Carcinoma: Results From a French Nationwide Study

Olivier Épaulard, Céline Villier, Philippe Ravaud et al. · Clinical Infectious Diseases · 2013 · 91 citations · Full text

Medicine, Dermatology, Oncology +17